A. Blázquez-Pérez

Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?

A. Gómez-Outes, M. Suárez-Gea, C. Pozo-Hernández, 2009, Journal of thrombosis and haemostasis : JTH.

Rivaroxaban versus enoxaparin after total knee arthroplasty

A. Gómez-Outes, M. Suárez-Gea, C. Pozo-Hernández, 2009, The Lancet.

Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison

A. García‐Arieta, Covadonga Álvarez, S. Morales-Alcelay, 2013, European Journal of Clinical Pharmacology.

Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients

J. Mar, R. San Miguel, A. Blázquez-Pérez, 2013, PharmacoEconomics.

Estimating chagas disease prevalence and number of underdiagnosed, and undertreated individuals in Spain.

A. Requena-Méndez, C. Subirá, A. Blázquez-Pérez, 2022, Travel medicine and infectious disease.

Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison

A. García‐Arieta, Covadonga Álvarez, S. Morales-Alcelay, 2012, European Journal of Clinical Pharmacology.

Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.

A. García‐Arieta, Covadonga Álvarez, S. Morales-Alcelay, 2012, International journal of pharmaceutics.